Learn About Urothelial Cancer

What is the definition of Urothelial Cancer?
Urothelial cancer, also known as transitional cell carcinoma, affects the kidney (renal) pelvis or ureter (tube) that drains urine from the kidney to the bladder and/or the lining of the inside of the bladder. It is the most common form of bladder cancer and occurs more frequently in men and older adults. The cause of urothelial cancer is unknown; however, some suspected causes are chronic irritation of the kidney from pain medicines, exposure to manufacturing chemicals and dyes, smoking or other tobacco use, past radiation exposure, and parasitic infections.
Save information for later
Sign Up
What are the symptoms of Urothelial Cancer?
Symptoms of urothelial cancer include fatigue, unexplained weight loss, loss of appetite, anemia, constant back pain, flank pain, pelvic pain, urinary urgency, pain, burning, or discomfort when urinating, or blood in urine (hematuria).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Urothelial Cancer?
Treatment for urothelial cancer includes surgery and chemotherapy. Bladder cancer can recur after treatment; therefore, long-term follow-up is necessary.
Who are the top Urothelial Cancer Local Doctors?
SP
Dr. Sumanta K. Pal
Oncology
Elite
Highly rated in
25
conditions
Oncology

City Of Hope Medical Foundation

1601 Avocado Ave 
Newport Beach, CA 92660

Sumanta Pal is an Oncologist in Newport Beach, California. Dr. Pal has been practicing medicine for over 19 years and is rated as an Elite doctor by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Urothelial Cancer, and Prostate Cancer. He is licensed to treat patients in California.

View Profile
AK
Dr. Ashish M. Kamat
Urology | General Surgery
Elite
Highly rated in
8
conditions
Urology
General Surgery

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Ashish Kamat is an Urologist and a General Surgeon in Houston, Texas. Dr. Kamat has been practicing medicine for over 28 years and is rated as an Elite doctor by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Bladder Cancer, Cystectomy, Muscle Invasive Bladder Cancer, and Urothelial Cancer. He is licensed to treat patients in Texas. Dr. Kamat is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
AB
Dr. Arjun V. Balar
Oncology
Elite
Highly rated in
14
conditions
Oncology

NYU Langone Health

NYU Medical Oncology Associates

160 E 34th St 
New York, NY 10016

Arjun Balar is an Oncologist in New York, New York. Dr. Balar has been practicing medicine for over 16 years and is rated as an Elite doctor by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Prostate Cancer, and Cystectomy. He is licensed to treat patients in New York. Dr. Balar is currently accepting new patients.

View Profile
View All Doctors
What are the latest Urothelial Cancer Clinical Trials?
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer
Who is this study for: Patients with Transitional Cell Carcinoma of Ureter
Status: Active, not recruiting
Start Date: May 2012
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Gemcitabine, Cisplatin
Phase: Phase 3
View Trial
Summary: POUT is a multi-centred randomised controlled phase III trial. 345 patients who have undergone nephro-ureterectomy, are surgically staged pT2-pT4, N0-3 or are pT1 and node positive, and who are fit for adjuvant chemotherapy, will be randomised to four cycles of adjuvant platinum based chemotherapy (experimental group) or surveillance (control group). Participants will be followed up according to r...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Status: Not yet recruiting
Start Date: May 3, 2022
View Trial
Summary: Background:~Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare. Some GU tumors are so rare that they are not included in treatment studies or tissue banks. This makes it hard for researchers to determine standards of care. Researchers want to learn...
View All Clinical Trials
What are the Latest Advances for Urothelial Cancer?
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Condition: Advanced Solid Tumors
Journal: Journal for immunotherapy of cancer
Treatment Used: Enoblituzumab and Pembrolizumab
Number of Patients: 133
Published: April 13, 2022
View publication
Summary: Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Genitourinary Cancers Following Kidney Transplant: Our 20 Years of Experience With Mechanistic Target of Rapamycin Inhibitors.
Condition: Genitourinary Cancers Following Kidney Transplant
Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
Treatment Used: Immunosuppression Reduction and Switching Rapamycin Inhibitors
Number of Patients: 827
Published: April 06, 2022
View publication
Summary: Genitourinary Cancers Following Kidney Transplant: Our 20 Years of Experience With Mechanistic Target of Rapamycin Inhibitors.
Tired of the same old research?
Check Latest Advances
Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplasty.
Condition: Bladder Cancer
Journal: BMJ case reports
Treatment Used: Pembrolizumab
Number of Patients: 1
Published: March 31, 2022
View publication
Summary: Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplasty.
View All Latest Advances